|Alternative Name :||ABT-450|
|Amount :||10 mg|
Molecular Formula: C40H43N7O7S
Molecular Weight: 765.9
Paritaprevir is an orally bioavailable, direct-acting inhibitor of the hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease.It inhibits HCV replication in stable Huh7-derived replicon cell lines infected with subgenomic genotypes 1a, 1b, 2a, 3a, 4a, and 6a (EC50s = 1, 0.21, 5.3, 19, 0.09, and 0.69 nM, respectively). It also inhibits replicons from clinical isolates of genotypes 1a (EC50s = 0.43-1.87 nM) and 1b (EC50s = 0.033-0.087 nM). Formulations containing paritaprevir in combination with ombitasvir, ritonavir, and dasabuvir with and without ribavirin have been used in the treatment of chronic HCV genotype 1 infection.
|Content :||Paritaprevir is supplied as a solid.|
|Storage condition :||Store at -20°C, product is stable for at least two years.|
For Research Use Only. Not for use in diagnostic/therapeutics procedures.